fluconazole has been researched along with Hematologic Malignancies in 56 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Excerpt | Relevance | Reference |
---|---|---|
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i." | 9.12 | An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006) |
"A 7-year retrospective analysis of candidemia in patients with hematologic malignancies demonstrated that ten patients, who received itraconazole and fluconazole during neutropenia, developed breakthrough fungemia caused by fluconazole-resistant Candida albicans (C." | 7.73 | Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. ( Kyo, T; Mikami, Y; Murayama, SY; Myoken, Y; Sugata, T, 2006) |
" krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 5.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
"5 mg/kg twice daily; N=248) with fluconazole oral solution or capsules (400 mg daily; N=246) in 494 patients with anticipated profound neutropenia (i." | 5.12 | An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. ( Andreesen, R; Bertz, H; Bodenstein, H; Boewer, C; Cornely, O; Dölken, G; Glasmacher, A; Hänel, M; Junghanss, C; Pasold, R; Ullmann, AJ; Wandt, H; Wedding, U; Wolf, HH, 2006) |
"A 7-year retrospective analysis of candidemia in patients with hematologic malignancies demonstrated that ten patients, who received itraconazole and fluconazole during neutropenia, developed breakthrough fungemia caused by fluconazole-resistant Candida albicans (C." | 3.73 | Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. ( Kyo, T; Mikami, Y; Murayama, SY; Myoken, Y; Sugata, T, 2006) |
"Candida krusei is inherently resistant to fluconazole and is emerging as a frequent cause of fungemia in patients with hematologic malignant neoplasms." | 3.70 | Candida krusei fungemia. An escalating serious infection in immunocompromised patients. ( Abbas, J; Abi-Said, D; Bodey, GP; Girgawy, E; Hachem, R; Hanna, HA; Mardani, M; Raad, I; Whimbey, E, 2000) |
"0 L and the bioavailability (F) was 81." | 2.90 | Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients. ( Ding, XL; Liu, LN; Miao, LY; Tian, JX; Xue, L; Yan, HH; Zhang, JJ; Zhang, WJ; Zhang, WW, 2019) |
"Micafungin treatment did not result in increasing adverse effects and had a safe profile as fluconazole in neutropenic patients." | 2.73 | Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation. ( Asakura, S; Fujii, N; Hara, M; Hiramatsu, Y; Ikeda, K; Maeda, Y; Matsuo, K; Matsuoka, KI; Miyata, A; Nawa, Y; Saito, T; Shinagawa, K; Sunami, K; Tabayashi, T; Tanimoto, M; Yano, T, 2008) |
"If fluconazole was administered orally, blood samples were drawn 2, 8, and 24 hr after ingestion of the drug." | 2.70 | Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy. ( Chiba, S; Hirai, H; Hirate, J; Kami, M; Kanda, Y; Kojima, N; Mori, S; Moriya, A; Saito, T; Sawada, Y; Yuji, K, 2001) |
"In neutropenic patients with hematologic malignancies, prophylaxis with fluconazole significantly decreased fungal isolation and other indicators of fungal infection when compared with amphotericin B." | 2.69 | Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy. ( Fujimori, Y; Kakishita, E; Kanamaru, A; Okada, M; Okamoto, T; Takatsuka, H; Takemoto, Y; Tamura, S; Wada, H, 1999) |
" Itraconazole has a broader spectrum of activity but the capsules give erratic bioavailability in neutropenic patients." | 2.69 | A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group. ( Morgenstern, GR; Prentice, AG; Prentice, HG; Ropner, JE; Schey, SA; Warnock, DW, 1999) |
"Fluconazole was discontinued when a neutrophil count above 1." | 2.69 | Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies. ( Goranov, S; Grudeva-Popova, J; Spasov, E; Vakrilov, V, 1999) |
"Fluconazole prophylaxis was given to 12 patients for a mean of 21." | 2.69 | Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial. ( Huijgens, PC; Simoons-Smit, AM; Timmers, GJ; Touw, D; van Loenen, AC; Zweegman, S, 2000) |
"The epidemiology of invasive fungal infections (IFIs) in immunocompromised individuals has changed over the last few decades, partially due to the increased use of antifungal agents to prevent IFIs." | 2.66 | Breakthrough invasive fungal infections: Who is at risk? ( Chen, SC; Cornely, OA; Hoenigl, M; Jenks, JD; Thompson, GR, 2020) |
"Invasive fungal diseases (IFD) are associated with considerable morbidity and mortality in patients with hematological malignancies." | 2.55 | [Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review]. ( Li, Y; Yu, L, 2017) |
"The fungal esophagitis in patients with hematologic malignancies was not rare." | 1.43 | [A clinical study of fungal esophagitis in 13 patients with hematologic malignancies]. ( Ai, H; Li, YF; Liu, YY; Mi, RH; Song, YP; Wei, XD; Zhang, LN; Zhou, YL, 2016) |
"Dose reductions of 50-75% for both sirolimus and tacrolimus, in combination with standard dosing of azole antifungal agents, were necessary to achieve therapeutic drug concentrations for immunosuppressants and potentially avoid toxicities." | 1.42 | Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation. ( Fung, HC; Peksa, GD; Schultz, K, 2015) |
"Most subjects (62%) had hematologic malignancies." | 1.39 | Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study. ( Lloyd, L; Meibohm, A; Schuster, MG; Strom, B, 2013) |
"Patients with oral mucositis assessment scale scores <20 had higher colonization rates than those with higher scores." | 1.39 | Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients. ( Freytes, CO; Kirkpatrick, WR; Patterson, TF; Redding, SW; Toro, JJ; Westbrook, SD; Wiederhold, NP, 2013) |
"Oral cheek mucosal specimens from 52 cancer patients receiving chemotherapy were cultured on CHROMagar Candida plates for Candida identification." | 1.35 | Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China. ( Lafleur, MD; Qi, C; Qi, QG; Sun, J, 2009) |
"Fluconazole was given to 17 paitents, intraconazole was given to 21 patients, and intraconazole to the other 9 patients after they had no effect with fluconazole." | 1.35 | [Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies]. ( Chen, SP; Shu, YG; Xu, YJ; Zhu, Y, 2008) |
"Neutropenia was the leading risk factor for all candidemia, whereas the catheter was the leading risk factor for C." | 1.35 | The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. ( Hachem, R; Hanna, H; Jiang, Y; Kontoyiannis, D; Raad, I, 2008) |
"Mucormycoses were diagnosed in six patients, (median age of 52 years; range, 26-74) treated between 2001-2004." | 1.33 | Mucormycoses in patients with hematologic malignancies: an emerging fungal infection. ( Bethge, WA; Einsele, H; Hebart, H; Horger, M; Kanz, L; Kröber, SM; Schmalzing, M; Schumacher, U; Stuhler, G, 2005) |
"Cryptococcosis in patients with hematologic malignancies is a rare complication." | 1.32 | Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. ( Caira, M; Caramatti, C; Cinieri, S; D'Antonio, D; Del Favero, A; Fianchi, L; Girmenia, C; Martino, B; Martino, P; Masini, L; Melillo, L; Pagano, L; Todeschini, G, 2004) |
"Fluconazole was effective as a single agent in 3 patients with solid tumors." | 1.31 | Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. ( Hachem, R; Minari, A; Raad, I, 2001) |
" krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen." | 1.31 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. ( Henslee-Downey, JP; Mehta, J; Safdar, A; Singhal, S; van Rhee, F, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 6 (10.71) | 18.2507 |
2000's | 34 (60.71) | 29.6817 |
2010's | 14 (25.00) | 24.3611 |
2020's | 2 (3.57) | 2.80 |
Authors | Studies |
---|---|
Garcia-Effron, G | 1 |
Kontoyiannis, DP | 1 |
Lewis, RE | 1 |
Perlin, DS | 1 |
Xue, L | 1 |
Zhang, WJ | 1 |
Tian, JX | 1 |
Liu, LN | 1 |
Yan, HH | 1 |
Zhang, WW | 1 |
Ding, XL | 1 |
Zhang, JJ | 1 |
Miao, LY | 1 |
Kanda, Y | 3 |
Kimura, SI | 1 |
Iino, M | 1 |
Fukuda, T | 1 |
Sakaida, E | 1 |
Oyake, T | 1 |
Yamaguchi, H | 1 |
Fujiwara, SI | 1 |
Jo, Y | 1 |
Okamoto, A | 1 |
Fujita, H | 1 |
Takamatsu, Y | 1 |
Saburi, Y | 1 |
Matsumura, I | 1 |
Yamanouchi, J | 1 |
Shiratori, S | 1 |
Gotoh, M | 1 |
Nakamura, S | 1 |
Tamura, K | 1 |
Jenks, JD | 1 |
Cornely, OA | 1 |
Chen, SC | 1 |
Thompson, GR | 1 |
Hoenigl, M | 1 |
Li, Y | 1 |
Yu, L | 1 |
Tang, L | 1 |
Yang, XF | 1 |
Qiao, M | 1 |
Zhang, L | 1 |
Tang, XW | 1 |
Qiu, HY | 1 |
Wu, DP | 1 |
Sun, AN | 1 |
Kung, HC | 1 |
Johnson, MD | 1 |
Drew, RH | 1 |
Saha-Chaudhuri, P | 1 |
Perfect, JR | 1 |
Peksa, GD | 1 |
Schultz, K | 1 |
Fung, HC | 1 |
Vuichard, D | 1 |
Weisser, M | 1 |
Orasch, C | 1 |
Frei, R | 1 |
Heim, D | 1 |
Passweg, JR | 1 |
Widmer, AF | 1 |
Zhou, YL | 1 |
Wei, XD | 1 |
Mi, RH | 1 |
Ai, H | 1 |
Zhang, LN | 1 |
Liu, YY | 1 |
Li, YF | 1 |
Song, YP | 1 |
Hiramatsu, Y | 1 |
Maeda, Y | 1 |
Fujii, N | 1 |
Saito, T | 2 |
Nawa, Y | 1 |
Hara, M | 1 |
Yano, T | 1 |
Asakura, S | 1 |
Sunami, K | 1 |
Tabayashi, T | 1 |
Miyata, A | 1 |
Matsuoka, KI | 1 |
Shinagawa, K | 1 |
Ikeda, K | 1 |
Matsuo, K | 1 |
Tanimoto, M | 1 |
Nawrot, U | 1 |
Nowicka, J | 1 |
Wlodarczyk, K | 1 |
Slobbe, L | 1 |
Waal, Lv | 1 |
Jongman, LR | 1 |
Lugtenburg, PJ | 1 |
Rijnders, BJ | 1 |
Wang, J | 1 |
Zhan, P | 1 |
Zhou, R | 1 |
Xu, J | 1 |
Shao, X | 1 |
Yang, Y | 1 |
Ouyang, J | 1 |
Sobrevilla Calvo, P | 1 |
Sun, J | 1 |
Qi, C | 1 |
Lafleur, MD | 1 |
Qi, QG | 1 |
Wingard, JR | 1 |
Carter, SL | 1 |
Walsh, TJ | 1 |
Kurtzberg, J | 1 |
Small, TN | 1 |
Baden, LR | 1 |
Gersten, ID | 1 |
Mendizabal, AM | 1 |
Leather, HL | 1 |
Confer, DL | 1 |
Maziarz, RT | 1 |
Stadtmauer, EA | 1 |
Bolaños-Meade, J | 1 |
Brown, J | 1 |
Dipersio, JF | 1 |
Boeckh, M | 1 |
Marr, KA | 1 |
Almyroudis, NG | 1 |
Segal, BH | 1 |
Schuster, MG | 1 |
Meibohm, A | 1 |
Lloyd, L | 1 |
Strom, B | 1 |
Zeuli, JD | 1 |
Wilson, JW | 1 |
Estes, LL | 1 |
Westbrook, SD | 1 |
Kirkpatrick, WR | 1 |
Wiederhold, NP | 1 |
Freytes, CO | 1 |
Toro, JJ | 1 |
Patterson, TF | 1 |
Redding, SW | 1 |
Pagano, L | 1 |
Fianchi, L | 1 |
Caramatti, C | 1 |
D'Antonio, D | 2 |
Melillo, L | 1 |
Caira, M | 1 |
Masini, L | 1 |
Todeschini, G | 1 |
Girmenia, C | 2 |
Martino, B | 1 |
Cinieri, S | 1 |
Martino, P | 2 |
Del Favero, A | 1 |
Di Bonaventura, G | 1 |
Spedicato, I | 1 |
Picciani, C | 1 |
Piccolomini, R | 1 |
Minenko, SV | 1 |
Zhukov, NV | 1 |
Chimishkian, KL | 1 |
Sokolova, EN | 1 |
Ptushkin, VV | 1 |
Kumar, CP | 1 |
Sundararajan, T | 1 |
Menon, T | 1 |
Venkatadesikalu, M | 1 |
Glasmacher, A | 4 |
Prentice, AG | 3 |
Vardakas, KZ | 1 |
Michalopoulos, A | 1 |
Falagas, ME | 1 |
Bethge, WA | 1 |
Schmalzing, M | 1 |
Stuhler, G | 1 |
Schumacher, U | 2 |
Kröber, SM | 1 |
Horger, M | 1 |
Einsele, H | 2 |
Kanz, L | 1 |
Hebart, H | 2 |
Cornely, O | 1 |
Ullmann, AJ | 1 |
Wedding, U | 1 |
Bodenstein, H | 1 |
Wandt, H | 1 |
Boewer, C | 1 |
Pasold, R | 1 |
Wolf, HH | 1 |
Hänel, M | 1 |
Dölken, G | 1 |
Junghanss, C | 1 |
Andreesen, R | 1 |
Bertz, H | 1 |
Shen, Q | 1 |
Song, XM | 1 |
Xu, XP | 1 |
Wang, JM | 1 |
Djulbegovic, B | 1 |
Myoken, Y | 1 |
Kyo, T | 1 |
Sugata, T | 1 |
Murayama, SY | 1 |
Mikami, Y | 1 |
Pazos, C | 1 |
Moragues, MD | 1 |
Quindós, G | 1 |
Pontón, J | 1 |
del Palacio, A | 1 |
de Vries, R | 1 |
Daenen, S | 1 |
Tolley, K | 1 |
Prentice, A | 1 |
Howells, S | 1 |
Christopherson, H | 1 |
de Jong-van den Berg, LT | 1 |
Postma, MJ | 1 |
Zhu, Y | 1 |
Chen, SP | 1 |
Shu, YG | 1 |
Xu, YJ | 1 |
Nomura, S | 1 |
Iishii, K | 1 |
Inami, N | 1 |
Kimura, E | 1 |
Urase, F | 1 |
Hachem, R | 3 |
Hanna, H | 1 |
Kontoyiannis, D | 1 |
Jiang, Y | 1 |
Raad, I | 3 |
Ellis, ME | 1 |
Spence, D | 1 |
Ernst, P | 1 |
Greer, W | 1 |
Nouwen, JL | 1 |
van Belkum, A | 1 |
de Marie, S | 1 |
Sluijs, J | 1 |
Wielenga, JJ | 1 |
Kluytmans, JA | 1 |
Verbrugh, HA | 1 |
Takatsuka, H | 1 |
Takemoto, Y | 1 |
Okamoto, T | 1 |
Fujimori, Y | 1 |
Tamura, S | 1 |
Wada, H | 1 |
Okada, M | 1 |
Kanamaru, A | 1 |
Kakishita, E | 1 |
Morgenstern, GR | 1 |
Prentice, HG | 2 |
Ropner, JE | 1 |
Schey, SA | 1 |
Warnock, DW | 1 |
Huijgens, PC | 2 |
Simoons-Smit, AM | 2 |
van Loenen, AC | 2 |
Prooy, E | 1 |
van Tinteren, H | 1 |
Ossenkoppele, GJ | 1 |
Jonkhoff, AR | 1 |
Löffler, J | 1 |
Hrastnik, C | 1 |
Daum, G | 1 |
Jarque, I | 1 |
Saavedra, S | 1 |
Martin, G | 1 |
Pemán, J | 1 |
Pérez Bellés, C | 1 |
Sanz, MA | 1 |
Goranov, S | 1 |
Spasov, E | 1 |
Grudeva-Popova, J | 1 |
Vakrilov, V | 1 |
Timmers, GJ | 1 |
Zweegman, S | 1 |
Touw, D | 1 |
Böhme, A | 1 |
Karthaus, M | 1 |
Hoelzer, D | 1 |
Salonen, JH | 1 |
Richardson, MD | 1 |
Gallacher, K | 1 |
Issakainen, J | 1 |
Helenius, H | 1 |
Lehtonen, OP | 1 |
Nikoskelainen, J | 1 |
Tuccinardi, C | 1 |
Santilli, S | 1 |
Mondello, F | 1 |
Monaco, M | 1 |
Cassone, A | 1 |
Abbas, J | 1 |
Bodey, GP | 1 |
Hanna, HA | 1 |
Mardani, M | 1 |
Girgawy, E | 1 |
Abi-Said, D | 1 |
Whimbey, E | 1 |
Trenschel, R | 1 |
Peceny, R | 1 |
Runde, V | 1 |
Elmaagacli, A | 1 |
Dermoumi, H | 1 |
Heintschel von Heinegg, E | 1 |
Müller, KD | 1 |
Schaefer, UW | 1 |
Beelen, DW | 1 |
Paterson, PJ | 1 |
McWhinney, PH | 1 |
Potter, M | 1 |
Kibbler, CC | 1 |
Minari, A | 1 |
Kami, M | 2 |
Sawada, Y | 1 |
Mori, S | 1 |
Hirate, J | 1 |
Kojima, N | 1 |
Moriya, A | 1 |
Yuji, K | 1 |
Chiba, S | 1 |
Hirai, H | 2 |
Safdar, A | 1 |
van Rhee, F | 1 |
Henslee-Downey, JP | 1 |
Singhal, S | 1 |
Mehta, J | 1 |
Machida, U | 1 |
Okuzumi, K | 1 |
Matsumura, T | 1 |
Mori Si, S | 1 |
Hori, A | 1 |
Kashima, T | 1 |
Takaue, Y | 1 |
Sakamaki, H | 1 |
Yoneyama, A | 1 |
Mutou, Y | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized Double-blind Trial of Fluconazole Versus Voriconazole for the Prevention of Invasive Fungal Infections in Allogeneic Blood and Marrow Transplant Patients (BMT CTN #0101)[NCT00075803] | Phase 3 | 600 participants (Actual) | Interventional | 2003-11-30 | Completed | ||
Collection of Granulocytes by Apheresis of Healthy Donors Stimulated With Filgrastim (G-CSF) and Dexamethasone[NCT01553214] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00075803)
Timeframe: day 42
Intervention | participants (Number) |
---|---|
Fluconazole | 11 |
Voriconazole | 9 |
Incidence of proven, probably, or presumptive IFI (NCT00075803)
Timeframe: 1 year
Intervention | percentage of patients (Number) |
---|---|
Fluconazole | 13.7 |
Voriconazole | 12.7 |
(NCT00075803)
Timeframe: 1 year
Intervention | percentage of patients (Number) |
---|---|
Fluconazole | 30.2 |
Voriconazole | 24.1 |
(NCT00075803)
Timeframe: 180 days
Intervention | percentage of patients (Number) |
---|---|
Fluconazole | 74.9 |
Voriconazole | 78.2 |
(NCT00075803)
Timeframe: 180 days
Intervention | days (Mean) | ||
---|---|---|---|
Number of days on study drug | Start day of empiric antifungal therapy | Days of empiric antifungal therapy | |
Fluconazole | 91 | 16 | 7 |
Voriconazole | 96 | 12 | 7 |
(NCT00075803)
Timeframe: 1 year
Intervention | participants (Number) | |||||||
---|---|---|---|---|---|---|---|---|
IFI after relapse/progression | IFI before engraftment | IFI who had failure to engraft | IFI after aGVHD (grades II-IV) | IFI while on study drug (up to day 100) | IFI after premature withdrawal of study drug | IFI after start other prophylaxis (not study drug) | IFI after empiric therapy | |
Fluconazole | 2 | 12 | 2 | 11 | 19 | 11 | 8 | 13 |
Voriconazole | 8 | 8 | 1 | 14 | 10 | 16 | 11 | 12 |
(NCT00075803)
Timeframe: 100, 180, and 365 days
Intervention | percentage of patients (Number) | ||
---|---|---|---|
100 days | 180 days | 365 days | |
Fluconazole | 85.4 | 80.0 | 70.2 |
Voriconazole | 90.1 | 81.2 | 67.8 |
(NCT00075803)
Timeframe: 100, 180, and 365 days
Intervention | percentage of patients (Number) | ||
---|---|---|---|
100 days | 180 days | 365 days | |
Fluconazole | 9.5 | 11.2 | 13.7 |
Voriconazole | 5.6 | 7.3 | 12.7 |
(NCT00075803)
Timeframe: 100, 180, and 365 days
Intervention | percentage of patients (Number) | ||
---|---|---|---|
100 days | 180 days | 365 days | |
Fluconazole | 83.1 | 74.9 | 63.3 |
Voriconazole | 86.1 | 73.9 | 61.2 |
(NCT00075803)
Timeframe: 100 and 365 days
Intervention | participants (Number) | ||
---|---|---|---|
Acute GVHD grade II-IV at day 100 | Acute GVHD grade III-IV at day 100 | Chronic GVHD at 1 year | |
Fluconazole | 132 | 42 | 138 |
Voriconazole | 116 | 27 | 137 |
Although there were 82 Galactomannan (GM) positives, 4 were excluded due to piperacillin/tazobactam administration, without other documentation of IFI, and were deemed false positives. (NCT00075803)
Timeframe: 1 year
Intervention | participants (Number) | |
---|---|---|
GM+ | GM- | |
Fluconazole | 43 | 252 |
Voriconazole | 35 | 270 |
9 reviews available for fluconazole and Hematologic Malignancies
Article | Year |
---|---|
Breakthrough invasive fungal infections: Who is at risk?
Topics: Adrenal Cortex Hormones; Antifungal Agents; Aspergillus; Candida; Central Venous Catheters; Echinoca | 2020 |
[Current Status and Future Perspectives of Primary Antifungal Prophylaxis in Patients with Hematological Malignancies-Review].
Topics: Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses | 2017 |
Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; | 2010 |
[Fungal infections in oncohematology: the role of prophylaxis].
Topics: Antifungal Agents; Antineoplastic Agents; Fever; Fluconazole; Hematologic Neoplasms; Humans; Mycoses | 2010 |
Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Topics: Amphotericin B; Antifungal Agents; Azoles; Clinical Trials as Topic; Echinocandins; Fluconazole; Hem | 2010 |
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses | 2005 |
Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Topics: Antifungal Agents; Chi-Square Distribution; Fluconazole; Hematologic Neoplasms; Hematopoietic Stem C | 2005 |
In meta-analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal infection in the treatment of haematological malignancy.
Topics: Antifungal Agents; Fluconazole; Hematologic Neoplasms; Humans; Itraconazole; Mycoses; Opportunistic | 2006 |
Antifungal prophylaxis in neutropenic patients with hematologic malignancies.
Topics: Antifungal Agents; Antineoplastic Agents; Aspergillosis; Aspergillus; Candida; Candidiasis; Fluconaz | 2000 |
14 trials available for fluconazole and Hematologic Malignancies
Article | Year |
---|---|
Multicenter-Based Population Pharmacokinetic Analysis of Ciclosporin in Hematopoietic Stem Cell Transplantation Patients.
Topics: Adolescent; Adult; Aged; Body Weight; Child; Child, Preschool; Cyclosporine; Dose-Response Relations | 2019 |
D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial.
Topics: Adult; Aged; Antifungal Agents; Febrile Neutropenia; Female; Fluconazole; Hematologic Neoplasms; Hem | 2020 |
Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Fluconazole; Hematologic Neoplasms; Humans; | 2014 |
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Echinocandins; Female; Fluconazole; Hematologic Neoplasm | 2008 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Child; Child, Preschool; Disease-Free Sur | 2010 |
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Double-Blind Method; Endpoint Determinati | 2006 |
Diagnostic potential of (1,3)-beta-D-glucan and anti-Candida albicans germ tube antibodies for the diagnosis and therapeutic monitoring of invasive candidiasis in neutropenic adult patients.
Topics: Adolescent; Adult; Aged; Amphotericin B; Anemia, Aplastic; Antibodies, Fungal; Antibody Specificity; | 2006 |
Fluconazole versus amphotericin B for the prevention of fungal infection in neutropenic patients with hematologic malignancy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Female; Fluconazole; | 1999 |
A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents, Phytogenic; Drug Interactions; Fe | 1999 |
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
Topics: Adult; Aged; Antifungal Agents; Double-Blind Method; Female; Fluconazole; Hematologic Neoplasms; Hem | 1999 |
Antifungal prophylaxis with low doses fluconazole in patients with hematological malignancies.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Hematologic Neoplasms; Humans; Male; Middle Aged; Myc | 1999 |
Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial.
Topics: Adolescent; Adult; Aged; Amphotericin B; Bilirubin; Consumer Product Safety; Contraindications; Fema | 2000 |
Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; Aspergillosis; | 2000 |
Serum levels of fluconazole in patients after cytotoxic chemotherapy for hematological malignancy.
Topics: Adult; Age Factors; Antifungal Agents; Antineoplastic Agents; Aspartate Aminotransferases; Dose-Resp | 2001 |
33 other studies available for fluconazole and Hematologic Malignancies
Article | Year |
---|---|
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Candida tropicalis; Candidiasis; Caspofungin; Drug Resis | 2008 |
Posaconazole vs. voriconazole in the prevention of invasive fungal diseases in patients with haematological malignancies: A retrospective study.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Child; China; Cost-Benefit Analysis; Female; Fluconazole | 2018 |
Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Algorithms; Antifungal Agents; Azoles; Drug Dosage Calculations; Female; Fluconazole; H | 2015 |
Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis.
Topics: Adult; Antifungal Agents; Candida; Candidemia; Candidiasis, Invasive; Drug Resistance, Fungal; Femal | 2014 |
[A clinical study of fungal esophagitis in 13 patients with hematologic malignancies].
Topics: Esophagitis; Fluconazole; Hematologic Neoplasms; Humans; Mycoses; Prognosis; Retrospective Studies; | 2016 |
Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from patients with hematological malignancies.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Fungal; Fluconazole; Hematologic Neoplasms | 2008 |
Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal Agents; An | 2009 |
Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China.
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Oral; China; DNA, F | 2009 |
Risk factors and outcomes of Candida krusei bloodstream infection: a matched, case-control study.
Topics: Adult; Aged; Antifungal Agents; Blood; Candida; Candidemia; Case-Control Studies; Culture Media; Dru | 2013 |
Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
Topics: Adult; Aged; Antifungal Agents; Drug Administration Schedule; Drug Therapy, Combination; Electrocard | 2013 |
Microbiology and epidemiology of oral yeast colonization in hemopoietic progenitor cell transplant recipients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Candida; Candida albicans; Candida glab | 2013 |
Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Cryptococcosis; Female; Fluconazole; Hematologic Neoplas | 2004 |
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Caspofungin; Colony Count, Microbial; Echin | 2004 |
[Prophylaxis of fungal infection in patients with hematologic neoplasms and severe neutropenia after high-dose chemotherapy].
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Antineoplastic Agents; Fluconazole; Hema | 2004 |
Candidosis in children with onco-hematological diseases in Chennai, south India.
Topics: Antifungal Agents; Candida; Candidiasis; Child; Cohort Studies; Drug Resistance, Fungal; Female; Flu | 2005 |
Mucormycoses in patients with hematologic malignancies: an emerging fungal infection.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Communicable Diseases, Emergi | 2005 |
[Pulmonary fungal infection in malignant hematological diseases: an analysis of 14 cases].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol | 2005 |
Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Topics: Candida albicans; Candidiasis; Drug Resistance; Fluconazole; Fungemia; Hematologic Neoplasms; Humans | 2006 |
Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Antineoplastic Agents; Cost-Benefit Analysis; Female; Fl | 2008 |
[Clinical features and treatment of invasive fungal infection in 47 patients with hematological malignancies].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Aspergillosis; Candidiasis; Female; Fluconazole; Hematol | 2008 |
Elevation of activated platelet-dependent chemokines and soluble cell adhesion molecules in patients with hematologic malignancies and high levels of beta-D-glucan.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; b | 2007 |
The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis; Catheterization, Central Venous; Cohort Stu | 2008 |
Variability of plasma fluconazole levels in patients with hematologic malignancy.
Topics: Alanine Transaminase; Antifungal Agents; Bilirubin; Candidiasis; Drug Interactions; Female; Fluconaz | 1997 |
Clonal expansion of Staphylococcus epidermidis strains causing Hickman catheter-related infections in a hemato-oncologic department.
Topics: Air Microbiology; Antibiotic Prophylaxis; Bacteriological Techniques; Catheterization, Central Venou | 1998 |
Phospholipid and sterol analysis of plasma membranes of azole-resistant Candida albicans strains.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Cell Membra | 2000 |
Delay of onset of candidemia and emergence of Candida krusei fungemia in hematologic patients receiving prophylactic fluconazole.
Topics: Antifungal Agents; Candidiasis; Female; Fluconazole; Fungemia; Hematologic Neoplasms; Humans; Male; | 2000 |
Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Cross Infection; | 2000 |
In vitro activity of fluconazole and voriconazole against isolates of Candida albicans from patients with haematological malignancies.
Topics: Antifungal Agents; Candida albicans; Candidiasis; Fluconazole; Hematologic Neoplasms; Humans; Microb | 2000 |
Candida krusei fungemia. An escalating serious infection in immunocompromised patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Antineoplastic Agents | 2000 |
The combination of oral amphotericin B with azoles prevents the emergence of resistant Candida species in neutropenic patients.
Topics: Amphotericin B; Antifungal Agents; Azoles; Bone Marrow Transplantation; Candida; Candidiasis; Drug R | 2001 |
Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Candida; Candidiasis; D | 2001 |
Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Topics: Adolescent; Adult; Antifungal Agents; Bacteremia; Bone Marrow Transplantation; Candida; Candidiasis; | 2001 |
Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Aspergillosis; Autopsy; Candidiasis; | 2002 |